华东医药股份有限公司 关于全资子公司产品及合作产品纳入国家医保及商保创新药目录的公告

Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security released a notification regarding the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory, as well as the Commercial Health Insurance Innovative Drug Directory for 2025 [1] - The company's subsidiary, Hangzhou Sino-American East Pharmaceutical Co., Ltd., has its product Ustinumab Injection adjusted to regular directory management, with changes in payment scope compared to the previous version [1] - The company's cooperative products, Senapali Capsules and Pentanoic Acid Linaclotide Capsules, have been included in the negotiated drug section, while Zewokiorunsai Injection is included in the Commercial Health Insurance Innovative Drug Directory [1] Group 2 - The new drug directory will officially take effect on January 1, 2026, and the relevant information regarding medical insurance payment standards and reimbursement details will be based on announcements from the National Healthcare Security Administration and other relevant government departments [1] - The inclusion of these products in the national medical insurance and commercial health insurance innovative drug directories is not expected to have a significant impact on the company's recent performance but is anticipated to assist in product market promotion in the future [1]